The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.
During the Ranexa® (ranolazine, A. Menarini) official launch symposium, renowned speaker Professor John Camm spoke on how ranolazine, a novel anti-anginal agent, could play a role in managing chronic stable angina (CSA). The session was followed by a lecture by Dr David Quek, who discussed the value of optimal medical therapy (OMT) in the management of CSA.
Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.
Dr. Wook Bum Pyun, Prof. Giuseppe Mancia, Assoc Prof. Tan Ru San, 20161108000000
Although there is some controversy surrounding the use of beta-blockers in patients with hypertension, third-generation agents such as nebivolol (Nebilet®, Menarini) function via unique mechanisms that improve upon the tolerability and haemodynamic profiles of older agents. At a recent Menarini-sponsored symposium held during the International Society of Hypertension 2016 meeting, Dr Wook Bum Pyun from the Ewha Womans University, Seoul, Korea, Professor Giuseppe Mancia from the University of Milano-Bicocca, Italy, and Associate Professor Tan Ru San from the National Heart Centre, Singapore, discussed these novel mechanisms and their effects on clinical outcomes.
Prof. Michael Weber, Prof. Giuseppe Mancia, Dr. Nelson Abelardo, 20161108000000
The use of beta-blockers in patients with cardiovascular (CV) disorders is somewhat controversial. However, many of the problems associated with traditional first- and second-generation beta-blockers may not be applicable to third-generation beta-blockers. Professor Michael Weber from the State University of New York, US, Professor Giuseppe Mancia from the University of Milano-Bicocca, Italy, and Dr Nelson Abelardo from the University of the Philippines, discussed the role of beta-blockers in managing patients with hypertension and chronic heart failure (CHF) at a recent Menarini-sponsored symposium held during the International Society of Hypertension 2016 meeting in Seoul, Korea, highlighting the potential benefits associated with newer beta-blockers such as nebivolol (Nebilet®, Menarini).
On 18th April 2015 at the Majestic Hotel Kuala Lumpur, A. Menarini invited two renowned experts in cardiology, Professor Athanasios Manolis and Dr Wong Teck Wee, to discuss about beta-blockers (BBs) with a focus on nebivolol, as well as the role of nitric oxide in the cardiovascular system.
At an Expert Panel Meeting organized by Menarini, Professor Athanasios J Manolis discussed about stable angina, with a focus on the role of ranolazine (Ranexa®, Menarini). Highlights of his talk are summarized below.
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.